Not logged in
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
SaveThe role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)
Harbeck, N.; Nitz, U. A.; Matthias, C.; Kates, R.; Braun, M.; Kummel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Grischke, E-M; de Haas, S. L.; Deurloo, R.; Schumacher, J.; Wuerstlein, R.; Kreipe, H. H.; Gluz, O.
Share
Save